Methandrostenolone (Dianabol) 20mg

Methandrostenolone 20mg (Dianabol) | NexorinPharma

Methandrostenolone 20mg is an oral anabolic steroid containing 20mg of Methandrostenolone per tablet. At NexorinPharma, we carry Methandrostenolone 20mg as part of our oral anabolic steroid inventory for customers in markets where Methandrostenolone is legally available.

Methandrostenolone is the active compound in this preparation, widely known under the brand name Dianabol. It is one of the most historically significant oral anabolic steroids ever developed and carries a well-documented presence in both clinical research and performance community discussions spanning several decades.

The 20mg per tablet concentration of this preparation represents a higher per-tablet dose than the 10mg format and consequently carries more pronounced side effect considerations per tablet. This page covers what Methandrostenolone is, how it works, and what health and legal considerations apply. It does not constitute medical advice, recommend steroid use, or provide dosage, cycle, or stacking guidance of any kind.

Product Specifications

About the 20mg Concentration

The 20mg per tablet concentration represents double the per-tablet dose of the standard 10mg Methandrostenolone format. Understanding this distinction is relevant for anyone researching this specific product and comparing it to other available Methandrostenolone concentrations.

Comparison With 10mg Format

The 10mg format is the most conservative concentration available among standard non-prescription Methandrostenolone presentations. The 20mg format delivers double the active compound per tablet. As a result, the dose-dependent side effect considerations associated with Methandrostenolone, particularly liver toxicity, estrogenic effects, and cardiovascular impact, are more pronounced per tablet at the 20mg concentration than at the 10mg format.

Comparison With Historical Clinical Formats

Historical pharmaceutical grade Dianabol tablets were available at 2.5mg and 5mg formats in US clinical settings before market withdrawal. The 20mg concentration consequently exceeds historical US pharmaceutical clinical tablet formats significantly. In addition, 10mg tablets were produced in several international markets where Methandrostenolone maintained prescription availability longer than in the United States.

Non-Prescription Market Context

Methandrostenolone 20mg is produced for markets where Methandrostenolone is legally available outside of prescription channels. It does not carry the manufacturing oversight, regulatory scrutiny, or clinical documentation of pharmaceutical grade prescription products. Quality, purity, and concentration accuracy are consequently less verifiable than with regulated products.

What Is Methandrostenolone

Methandrostenolone is a synthetic anabolic-androgenic steroid derived from testosterone. CIBA developed it in the late 1950s and introduced it to the US market under the brand name Dianabol in 1958. From the beginning, it was one of the first anabolic steroids specifically developed for performance enhancement alongside its clinical applications. It consequently became one of the most widely used and discussed oral anabolic steroids in history.

Structurally, Methandrostenolone is a modified form of testosterone. A methyl group at the 17-alpha position allows it to survive first-pass liver metabolism when taken orally. In addition, a double bond between carbon atoms 1 and 2 of the steroid structure reduces its androgenic activity relative to testosterone while preserving strong anabolic activity. These structural modifications produce an oral anabolic steroid with significant anabolic potency and meaningful estrogenic activity through aromatization.

The resulting pharmacological profile produces an anabolic rating of 90 to 210 and an androgenic rating of 40 to 60 relative to a testosterone baseline of 100. Strong anabolic activity combined with significant estrogenic conversion and notable liver toxicity consequently defines Methandrostenolone’s pharmacological profile.

How Methandrostenolone Works

Methandrostenolone is active when taken orally. The 17-alpha alkylation allows it to pass through the liver without complete breakdown, reaching systemic circulation in active form.

Androgen Receptor Binding

Methandrostenolone binds to androgen receptors throughout the body. Its androgenic rating of 40 to 60 is lower than testosterone’s baseline of 100, reflecting its reduced androgenic activity relative to its anabolic potency. As a result, androgen receptor activation in muscle tissue drives its anabolic effects while producing comparatively lower androgenic activity in androgen-sensitive tissues than testosterone-based compounds.

Nitrogen Retention

Methandrostenolone produces very strong positive nitrogen retention in muscle tissue. The body retains significantly more nitrogen than it excretes. Consequently, this produces a pronounced anabolic environment that strongly favors rapid muscle repair and growth. This mechanism is one of the most consistently referenced pharmacological characteristics of Methandrostenolone in both clinical and performance community discussions.

Protein Synthesis

Methandrostenolone accelerates protein synthesis in skeletal muscle tissue at a rate consistent with its high anabolic rating. Faster protein synthesis supports rapid muscle repair and growth following training. This mechanism is directly tied to its androgen receptor activity and contributes to the rapid mass accumulation observations consistently reported in performance community discussions.

Aromatization to Estrogen

Methandrostenolone converts to estrogen through the aromatase enzyme pathway. This aromatization produces significant estrogen elevation and drives estrogenic side effects including water retention, gynecomastia, and mood changes. As a result, estrogen management is a primary consideration with Methandrostenolone use. At the 20mg concentration, estrogenic side effect management is consequently more relevant than at the lower 10mg format.

Glycogenolysis

Methandrostenolone enhances glycogenolysis, improving muscular energy availability during training. This mechanism is one of the consistently documented pharmacological characteristics of Methandrostenolone and contributes to the strength and performance observations discussed in performance communities. Furthermore, this glycogenolytic effect distinguishes Methandrostenolone from anabolic steroids that do not produce meaningful glycogenolytic activity.

IGF-1 Stimulation

Methandrostenolone increases Insulin-like Growth Factor 1 production. IGF-1 plays a direct role in muscle repair, recovery, and anabolic activity throughout the body. This mechanism consequently contributes to the recovery-related observations consistently reported in performance community discussions about Methandrostenolone use.

Clinical Background

Methandrostenolone carries a documented clinical history that provides relevant context for its pharmacological profile.

Original Clinical Development

CIBA developed Methandrostenolone in the late 1950s with specific clinical applications including treatment of hypogonadism, osteoporosis, and muscle wasting conditions. It was FDA approved and commercially available in the United States under the Dianabol brand name from 1958. The FDA subsequently withdrew its approval in 1985 after CIBA discontinued marketing the drug, though it continued production in other countries.

Muscle Wasting and Osteoporosis

Methandrostenolone was used clinically for the treatment of muscle wasting conditions and osteoporosis. Its potent anabolic effects on muscle tissue and bone provided clinical relevance for these indications. This clinical history consequently provides a broader research base for understanding its pharmacological profile and documented anabolic effects in human subjects.

Research Context

The extensive clinical and observational research base accumulated across decades of Methandrostenolone use provides one of the most comprehensive pharmacological documentation bases of any oral anabolic steroid. This research consequently informs the well-characterized side effect profile and pharmacological understanding of the compound across both clinical and performance contexts.

Methandrostenolone 20mg Versus Other Oral Anabolic Steroids

Versus Methandrostenolone 10mg

Both preparations contain the same active compound with identical pharmacological profiles. The 20mg format delivers double the active Methandrostenolone per tablet compared to the 10mg format. As a result, the dose-dependent side effect considerations are more pronounced per tablet at the 20mg concentration. The 10mg format provides more conservative per-tablet dosing than the 20mg format.

Versus Oxymetholone (Anadrol)

Oxymetholone is a more potent oral anabolic steroid with a higher anabolic rating than Methandrostenolone. Both compounds produce estrogenic effects through different mechanisms. Oxymetholone produces estrogenic activity through direct estrogen receptor activation rather than conventional aromatization, while Methandrostenolone aromatizes directly to estrogen. Both are 17-alpha alkylated with significant liver toxicity. Oxymetholone consequently represents a more aggressive compound than Methandrostenolone across most pharmacological parameters.

Versus Oxandrolone (Anavar)

Oxandrolone is a non-aromatizing oral anabolic steroid with significantly milder liver toxicity than Methandrostenolone. Compared to the 20mg Methandrostenolone format, Oxandrolone produces no estrogenic conversion, lower liver stress, and a significantly more favorable overall side effect profile. These two compounds consequently occupy fundamentally different positions on the oral anabolic steroid potency and risk spectrum.

Versus Stanozolol (Winstrol)

Stanozolol is a non-aromatizing oral anabolic steroid with significant liver toxicity. Unlike Methandrostenolone, Stanozolol does not produce estrogenic effects through aromatization. Both carry 17-alpha alkylation-related liver toxicity. However, Methandrostenolone’s significant aromatization profile at the 20mg concentration produces a fundamentally different and more pronounced estrogenic side effect consideration than Stanozolol.

Versus Turinabol

Turinabol is a non-aromatizing oral anabolic steroid structurally derived from Methandrostenolone. A chlorine atom added to the structure prevents aromatization, producing a compound with lower anabolic activity than Methandrostenolone but without the significant estrogenic side effects. Turinabol consequently represents a milder non-estrogenic alternative to both the 10mg and 20mg Methandrostenolone formats.

Side Effects and Health Risks

Methandrostenolone 20mg carries a well-documented side effect profile. The higher 20mg concentration per tablet compared to the 10mg format makes side effect considerations more pronounced across all risk categories.

Liver Toxicity

Liver toxicity is the most serious health concern associated with Methandrostenolone use. As a 17-alpha alkylated oral steroid, the alkylation that allows oral bioavailability places significant and direct stress on liver tissue. Clinical research and case reports document elevated liver enzymes and in cases of prolonged or high-dose use, more serious hepatic complications. At the 20mg concentration, these liver stress considerations are more relevant than at the 10mg format. Liver monitoring through regular blood work is therefore essential for anyone using this compound.

Estrogenic Effects

Methandrostenolone converts significantly to estrogen through the aromatase enzyme pathway. Elevated estrogen levels consequently produce water retention, gynecomastia, and mood changes. At the 20mg concentration, estrogenic side effect management is more relevant than at the lower 10mg format. Aromatase inhibitors are commonly referenced in performance communities for managing estrogen conversion with Methandrostenolone use.

Cardiovascular Effects

Methandrostenolone produces significant adverse lipid profile changes. HDL cholesterol drops sharply while LDL cholesterol increases substantially. Furthermore, water retention from estrogenic activity contributes to elevated blood pressure. At the 20mg concentration, these cardiovascular considerations are more pronounced than at the 10mg format. Regular cardiovascular monitoring is therefore essential for anyone using this compound.

Hormonal Suppression

Methandrostenolone suppresses the hypothalamic-pituitary-gonadal axis and the body’s natural testosterone production. Post-use hormonal disruption can persist for months. In some cases, it results in long-term or permanent hypogonadism requiring ongoing medical treatment. Hormonal monitoring is consequently a relevant health consideration for anyone using this compound.

Androgenic Effects

Despite its relatively low androgenic rating, Methandrostenolone still produces androgenic side effects in susceptible individuals. These include accelerated hair loss in genetically predisposed individuals and acne. In women, virilization risks are serious considerations even at lower doses. At the 20mg concentration, these androgenic considerations are consequently more pronounced than at the 10mg format.

Blood Pressure

Water retention from estrogenic activity and adverse lipid changes both contribute to blood pressure increases with Methandrostenolone use. At the 20mg concentration, blood pressure monitoring is consequently more relevant than at the 10mg format.

Psychological Effects

Anabolic steroid use carries documented associations with mood changes and irritability. These considerations apply to Methandrostenolone use at any concentration and are consequently more pronounced at the 20mg format than at the lower 10mg concentration.

Legal and Regulatory Status

Methandrostenolone carries Schedule III controlled substance status in the United States under the Controlled Substances Act. The FDA withdrew its approval in 1985 after CIBA discontinued marketing. Possession without a valid prescription is consequently a federal offense.

In the United Kingdom, Methandrostenolone falls under Class C of the Misuse of Drugs Act. Supply is illegal.

The World Anti-Doping Agency bans Methandrostenolone alongside all major athletic governing bodies. As a result, it appears on prohibited substance lists across Olympic sports, professional athletics, and competitive bodybuilding organizations that conduct testing.

You are responsible for confirming the legal status of Methandrostenolone in your specific jurisdiction before purchasing from NexorinPharma.

Frequently Asked Questions

Is Methandrostenolone 20mg Available at NexorinPharma

Yes. NexorinPharma carries Methandrostenolone 20mg for customers in markets where Methandrostenolone is legally available. Visit nexorinpharma.com to check current availability and pricing.

What Is the Half-Life of Methandrostenolone

Methandrostenolone produces a half-life of approximately 3 to 6 hours. As a result, its relatively short half-life requires regular daily administration to maintain stable plasma concentrations throughout the day.

How Does the 20mg Concentration Differ From the 10mg Format

Both preparations contain the same active Methandrostenolone compound with identical pharmacological profiles. The 20mg format delivers double the active compound per tablet compared to the 10mg format. As a result, the dose-dependent side effect considerations are more pronounced per tablet at the 20mg concentration.

Does Methandrostenolone Aromatize

Yes. Methandrostenolone converts significantly to estrogen through the aromatase enzyme pathway. Consequently, estrogenic side effects including water retention and gynecomastia are primary health considerations with this compound, particularly at the higher 20mg concentration.

What Are the Most Serious Health Risks

Liver toxicity from 17-alpha alkylation is the most serious health concern with Methandrostenolone. In addition, cardiovascular effects from significant lipid dysregulation and water retention, estrogenic effects including gynecomastia and water retention, and hormonal suppression complete the primary risk profile. These considerations are furthermore more pronounced at the 20mg concentration than at the 10mg format. Medical supervision and regular blood work monitoring are therefore essential for anyone using this compound.

Is Methandrostenolone 20mg Legal to Purchase

Methandrostenolone carries Schedule III controlled substance status in the United States. Legal status varies by jurisdiction. You are consequently responsible for confirming the legal status in your jurisdiction before purchasing from NexorinPharma.

What to Consider Before Purchasing Methandrostenolone 20mg

Methandrostenolone has one of the most extensively documented pharmacological profiles of any oral anabolic steroid. Decades of clinical research, observational data, and performance community discussion provide a substantial body of information about its effects and risk profile. That research base consequently applies to its pharmacological profile regardless of the specific concentration format.

The 20mg concentration delivers double the active compound per tablet compared to the 10mg format. As a result, the dose-dependent side effect considerations are more pronounced at the 20mg concentration and the clinical research base at lower historical clinical doses does not fully reflect the risk profile at this higher concentration.

Methandrostenolone carries documented liver, cardiovascular, estrogenic, hormonal, androgenic, and psychological health risks. These risks require medical supervision to manage responsibly. Regular blood work monitoring including liver enzymes, lipid panels, estrogen levels, and hormone levels is therefore essential for anyone using this compound.

For customers in markets where Methandrostenolone is legally available, visit nexorinpharma.com to check current Methandrostenolone 20mg availability, pricing, and stock levels.